🇺🇸 FDA
Pipeline program

LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules

E7386-G000-201

Phase 2 small_molecule active

Quick answer

LENVIMA 4 mg hard capsules, E7386, KEYTRUDA 25 mg/mL concentrate for solution for infusion, E7386, LENVIMA 10 mg hard capsules for colorectal cancer, melanoma, hepatocellular carcinoma is a Phase 2 program (small_molecule) at Eisai GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Eisai GmbH
Indication
colorectal cancer, melanoma, hepatocellular carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials